Gene treatment for Chlamydia

There might be a treatment for Chlamydia — the most common sexually transmitted bacterial infection in the world — now. Researchers at the University of Waterloo have developed a new way to prevent and treat the infection.

The new treatment differs from traditional antibiotic treatment as it is a type of gene therapy that is delivered via nanotechnology and has shown a 65 per cent success rate in preventing chlamydia infection on a single dose.

Speaking about it, lead author Emmanuel Ho said, “As antibiotic resistance continues to develop, people may experience Chlamydia infections that cannot be treated through conventional means, which is causing increasing public health challenges.” “If left untreated or if it takes an extended period of time it can lead to infertility and other reproductive issues so finding new ways to treat this common infection is important,” said Ho, adding, “As the Food and Drug Administration in the United States has recently approved the first siRNAbased drug for market, we are hopeful this kind of research will be able to be widely available in the future.” The new treatment created by Ho targets Chlamydia infection by preventing the majority of bacteria from entering cells in the genital tract and destroying any bacteria that is able to penetrate a cell wall. The team was able to achieve this by using a small interfering ribonucleic acid to target a specific gene called PDGFR-beta in the female reproductive tract, which creates a protein that binds to Chlamydia bacteria.

Speaking about it, Ho said, “By targeting PDGFR-beta we are able to stop the creation of the protein that Chlamydia will use to enter genital tract skin cells. As a result, an incoming infection has fewer targets to latch onto and infection is less likely to occur,” he added.